# Absolute Bioavailability Study With Bexagliflozin

> **NCT03417076** · PHASE1 · WITHDRAWN · sponsor: **Theracos**

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Bexagliflozin

## Key facts

- **NCT ID:** NCT03417076
- **Lead sponsor:** Theracos
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-08-01
- **Primary completion:** 2018-09-16
- **Final completion:** 2018-09-16
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor decision to not initiate study due to sufficient bioavailability information
- **Last updated:** 2019-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03417076

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03417076, "Absolute Bioavailability Study With Bexagliflozin". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03417076. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*